Kornimate/medical-research-clean huggingface dataset:
periodontal granulation tissue preservation in surgical periodontitis treatment

Conditions: Periodontal Pocket; Periodontal Diseases; Periodontal Bone Loss

Summary: the objective of this study will be to evaluate a new protocol for the surgical treatment of periodontal disease with two novelties: to make a single incision in the midline of the interproximal area to respect the vascular supply and preserve the granulation tissue with regenerative potential. the investigators will carry out a controlled and randomized clinical trial with a control group (n=25; modified kirkland flap) and a test group (n=25; experimental surgical protocol: incision in the mid-interproximal area of the papilla and preservation of the granulation tissue). clinical parameters will be taken at the time of surgery and 12 months follow-up: bleeding on probing (bop), clinical attachment level (cal), residual probing depth (rpd),probing pocket depth reduction (ppdr), recession (rec), interproximal gingival recession (igr), width of keratinized gingiva (kt), gain of supra-alveolar clinical attachment (supra-ag), early wound healing index (ehi).


Eligibility criteria:
inclusion criteria: * stage iii or iv periodontitis, including all grades. * unresolved deep pockets (probing pocket depth \[ppd\] \>5 mm + bop) 4 to 6 weeks after non-surgical treatment. * interproximal plaque index \<35% maintained during periodontal treatment and maintenance. * adherence to periodontal maintenance appointments. exclusion criteria: * systemic disease contraindicating periodontal surgery. * teeth with incorrect endodontic treatment or restoration. * stage i or ii periodontitis.
study of radioimmunoguided intensity modulated radiotherapy (imrt) for prostate cancer

Conditions: Prostatic Neoplasm

Summary: the current study involves a novel and aggressive therapeutic approach for patients' prostate cancer. in addition, the investigators propose to administer hormonal therapy to patients with an especially high risk: those with initial gleason scores of \> 6, psa \> 10 ng/ml, t3/t4 primary tumors, and those found to be node positive (n+). the use of hormonal therapy in these specific settings correlates with our current standard of care. imrt is better able to spare and protect normal tissues from receiving radiation than 3-d conformal rt. the radiotherapy would be followed by continued hormonal therapy for a total of 6 months in those who have one of the following gleason 7 and psa 10-20 and as per the previous version of this trial, 1 year similar to that delivered by the eortc for higher risk patients, (those with initial gleason scores of \> 8, psa \> 20 ng/ml, or t3/t4 tumors). those found to be n(+) would have the hormonal therapy continued indefinitely or until disease progression occurred in a manner analogous to the messing et. al. series in prostatectomy patients. the goals are to develop and administer a program of treatment that includes the most recent developments in imaging, integrating data from both the ct scan and the prostascint scan to optimize prostate cancer rt. the ct scan will be used for staging and to determine the exact location of the entire prostate which will receive a reasonable dose of rt. the prostascint will be used to assess the spread of disease to lymph nodes as well as to determine the exact location of the tumor within the prostate gland. this region will then be boosted to a tumorcidal dose. the investigators then plan to monitor the toxicity and outcome of this treatment. the investigators expect that this program of radioimmunoguided imrt will likely result in similar or less toxicity and increased cure rates when compared to conventional radiotherapy and standard imrt programs.


Eligibility criteria:
inclusion criteria: * patients with pathologically proven prostate cancer * no evidence of distant metastases (m0) on physical examination, bone scan * ecog ps 0,1,2 * adequate organ function as evidenced by: * hemoglobin \> 10.0 gm/dl * white blood count \> 3000/mcl * platelet count \> 90,000/mcl * ast \< 2x normal * age \> 18 years * patients can not be allergic to leuprolide or goserelin if the pretreatment psa \> 20, gleason score \> 8, t3/4, or n1 disease * written informed consent * we anticipate enrolling at least 50 patients per year, which would bring accrual to projected total of 100 patients in 2 years exclusion criteria: * none
dose-ranging study in patients with chronic obstructive pulmonary disease (copd)

Conditions: COPD

Summary: the trial is designed to identify an appropriate dose of qab149 for delivery via a multiple dose inhaler for use in the copd phase iii program.


Eligibility criteria:
inclusion criteria: * diagnosis of copd * age 40-75 years * smoking history exclusion criteria: * other serious disease * allergy to qab149 * respiratory tract infection

Keywords: copd, adults, qab149
correlation between micro vascular complications and severity of coronary artery disease in type 2 dm

Conditions: Patients With Type 2 DM Who Underwent Coronary Angiography Due to Coronary Artery Disease and Presence of Microvascular Complications in Same Patients

Summary: diabetes is a major cause of morbidity and mortality worldwide and it contributes substantially to healthcare costs. type 2 diabetes mellitus is the most common type of diabetes accounting for approximately (90%) of all cases. type 2 dm carries a two to six times risk of death from cardiovascular etiologies, such that age adjusted prevalence of white americans for coronary artery disease (cad) is double in those with type 2 dm than those without .


Eligibility criteria:
inclusion criteria: 100 cases were selected with type ii (dm) patients who had been admitted for coronary angiography because of suspected (cad) to the catheter lab unit of sohag university hospital. exclusion criteria: 1. type 1 dm. 2. smoker. 3. hypertension. 4. pregnant women. 5. patient known non diabetic retinal disease non diabetic. nephropathy or neuropathy. 6. history of familial dyslipidemia.
impact of pulmonary rehabilitation on direct healthcare costs in chronic obstructive pulmonary disease (copd)

Conditions: COPD

Summary: the purpose of this study is to study the direct cost of illness study of copd patients who participated in a pulmonary rehabilitation program for 8 weeks.


Eligibility criteria:
inclusion criteria: * copd exclusion criteria: * none

Keywords: copd pulmonary rehabilitation
retrospective real world oxbryta® data collection and analysis study

Conditions: Sickle Cell Disease

Summary: the aim of this study is to collect and analyze retrospective data on oxbryta in a real-world setting. this is a multicenter, retrospective data collection and analysis study to characterize health outcomes in approximately 300 patients with scd who have been treated with oxbryta as part of their usual care. any patient with scd who received oxbryta treatment for at least 2 weeks as part of their usual care according to the oxbryta us prescribing information (uspi) is eligible to participate. study data from 1 year before and up to 1 year after the first dose of oxbryta will be entered in case report forms (crfs) via an electronic data capture (edc) system by the study staff.

the following are categories of interest in patients with scd treated with oxbryta: * clinical outcomes, as assessed by clinical and laboratory assessments of hematological parameters and end organ damage, and incidence of significant clinical events * healthcare resource utilization * health-related quality of life (hrqol), as assessed by patient-reported outcome (pro) measures and clinician-reported outcomes (clinro) the safety objective is to assess the safety and tolerability of oxbryta.

Eligibility criteria:
inclusion criteria: patients who meet all the following criteria will be eligible for inclusion in this study: 1. willing and able to provide written informed consent (ages greater or equal to 18 years) or parental/guardian consent and patient assent (age \<18 years), as required by the irb or institution or irb, per local regulations 2. male or female patients with documented diagnosis of scd (all genotypes) 3. have been treated with oxbryta for at least 2 weeks, according to the oxbryta uspi exclusion criteria: -

Keywords: sickle cell disease registry
cerebral autoregulation guiding blood pressure management after revascularization

Conditions: Ischemic Stroke; Revascularization; Blood Pressure; Cerebrovascular Insufficiency; Cerebral Autoregulation; Individuation; Hemorrhagic Transformation Due to Acute Stroke

Summary: this clinical trial aims to learn whether blood pressure (bp) guided by individualized cerebral autoregulation (ca) is safe and provides a better prognosis than a fixed target in patients with ischemic stroke after endovascular therapy. the bp of participants will be managed at least 48 hours after revascularization. researchers will compare the ca-guided bp group with the fixed target bp group to mainly see if individualized bp could help more patients to have their neurological function improved at seven days.


Eligibility criteria:
inclusion criteria: * acute ischemic stroke, undergone endovascular treatment within 24 hours of onset (time of stroke is the last known normal for wake-up stroke or with unknown onset time), with reaching the goal of mtici grade 2b-3 * no functional disability before stroke (mrs 0-1) * angiography (cta, mra or dsa) before endovascular therapy confirmed occlusion of the internal carotid artery and/or the middle cerebral artery m1 to m2 segment, with consistent clinical symptoms. * informed consent is given by the patient or the legal representative. exclusion criteria: * hemorrhagic transformation with mass effect (ph-2 type parenchymal hematoma) occurs during the operation. * coma, dilated pupils on one or both sides, dull or absent light reflex is noticed before randomization * dissection of aorta, common carotid artery, internal carotid artery, subclavian artery, intracranial artery; severe bilateral subclavian artery stenosis; contraindications of radial artery puncture were found before or during surgery. * shock. * severe cardiomyopathy with heart failure (egfr ≤ 30% or nyha grade iv), acute myocardial infarction, or unstable angina. * possible infective endocarditis, infective embolism, or vasculitis. * participating in other clinical research involving drug or device intervention after endovascular therapy. * women who plan or are pregnant, or breastfeeding. * severe liver or kidney disease, malignant tumor with a life expectancy is less than 3 months. * the 90-day follow-up is not expected to be completed.

Keywords: ischemic stroke revascularization blood pressure cerebral autoregulation
safety and cognitive function study of evp-6124 in patients with mild to moderate alzheimer's disease

Conditions: Alzheimer's Disease; Central Nervous System Diseases; Cognition

Summary: this study is being conducted to determine the safety and effect on cognitive function of the investigational medication, evp-6124, in individuals with mild to moderate probable alzheimer's disease.

this is a randomized, double-blind, placebo-controlled, parallel, 24-week, phase 2 safety/efficacy study in which three dose levels of evp-6124 or placebo will be evaluated. eligible for enrollment will be patients who meet clinical criteria for mild to moderate probable alzheimer's disease who are either receiving treatment with achei medication at a stable dose or who are not presently taking any achei or memantine co-medication. patients will be randomized to one of the following groups: 0.3 mg, 1 mg or 2 mg or placebo. approximately 400 subjects will be randomized to the 4 treatment groups. study drug will be supplied as capsules and will be orally administered once daily for a total of 24 weeks.

Eligibility criteria:
inclusion criteria: * subjects with probable alzheimer's disease * mini-mental state examination (mmse) score of 14 to 24 inclusive at screening and a cdr-sb score ≥2 at the screening assessment * modified hachinski ischemic score (mhis) ≤4 at screening * female subjects are ≥1 year post-menopausal or are surgically sterile * caregiver available; if not living in the same household, caregiver sees subject at least four times each week * subject living at home, senior residential setting, or an institutional setting without the need for continuous nursing care * general health status acceptable for participation in a 24 week clinical trial be administered exclusion criteria: general * participation in another therapeutic clinical trial within 30 days before baseline * prior participation in an amyloid vaccination clinical study * inability to swallow capsules * likely inability to complete 24 week study * inability to be ≥75% compliant with single-blind placebo run-in medication * inability to adequately perform cognitive tests * history of significant cardiovascular disease * major depression * psychosis * history of stroke within 18 months of screening * head trauma * inability to perform any screening or baseline evaluations

Keywords: alzheimer's disease central nervous system diseases cognition
cyclophosphamide plus t-cell transplantation for patients with hematologic malignancies

Conditions: Leukemia; Myelodysplastic Syndromes

Summary: rationale: drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of abnormal blood cells, either by killing the cells or by stopping them from dividing. giving cyclophosphamide together with donor lymphocytes that have been treated in the laboratory may be an effective treatment for myelodysplastic syndromes or myeloproliferative disorders. purpose: this clinical trial is studying the best dose of donor lymphocytes when given together with cyclophosphamide in treating patients with myelodysplastic syndromes or myeloproliferative disorders.

objectives: * determine the maximum tolerated dose of allogeneic cd8-positive t-cell-depleted, haploidentical donor lymphocytes when given after cyclophosphamide in patients with myelodysplastic syndromes or myeloproliferative disorders. outline: patients receive cyclophosphamide on days 1 and 2. patients then undergo infusion of allogeneic t-cell depleted donor lymphocytes on day 3. cohorts of patients receive escalating doses of cd8-positive t-cell-depleted haploidentical donor lymphocytes until the maximum tolerated dose is determined. projected accrual: a total of 44 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of 1 of the following: * myelodysplastic syndromes (mds) * international prognostic scoring system (ipss) score ≥ intermediate-2 * chronic myelomonocytic leukemia * acute myeloid leukemia arising from mds * must have failed or are ineligible for or intolerant to treatment with azacitidine * patients with normal marrow cytogenetics or an isolated 5q- abnormality must have failed or are ineligible for or intolerant to treatment with lenalidomide * patients who are hla-dr15-positive must have failed or are ineligible for pharmacologic immunosuppression (e.g., anti-thymocyte globulin, cyclosporine, steroids) * no presence of cytotoxic antibodies against donor lymphocytes * no hla-identical donor available or ineligible for hla-identical allogeneic bone marrow transplantation * hla partially mismatched (haploidentical) related donor available * first-degree related donor, including half-siblings or first cousins * inherited recombinant haplotype from parents allowed if donor shares ≥ 1 hla antigen at each of the hla-a, -b, and dr loci patient characteristics: * ecog performance status (ps) 0-1 or karnofsky ps 80-100% * bilirubin \< 3.0 mg/dl * ast and alt ≤ 4 times upper limit of normal * creatinine \< 3.0 mg/dl * lvef \> 35% prior concurrent therapy: * see disease characteristics * recovered from prior therapy * no prior transfusions from donor * at least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin c) or radiotherapy * no other concurrent investigational drugs

Keywords: previously treated myelodysplastic syndromes secondary myelodysplastic syndromes secondary acute myeloid leukemia chronic myelomonocytic leukemia de novo myelodysplastic syndromes
mopexe and re in treating dysmenorrhea

Conditions: Dysmenorrhea; Gynecologic Disease

Summary: the aim of this study is to compare the effects of motor imagery focused pelvic floor exercises and relaxation exercises used in the treatment of dysmenorrhea on pain and menstrual symptoms.

quantitative research methods were used in the study and it was a randomized type study. the sample of the study consisted of women between the ages of 18-30 who volunteered to participate in the study, showed symptoms of dysmenorrhea and can be accessed online. the names of female participants who volunteered to participate in the study and met the inclusion criteria were written on papers and put in a bag. papers will be randomly selected by the evaluator by drawing lots. participants will be randomly divided into 3 groups: motor imagery focused pelvic floor exercise group, relaxation exercise group, and combined group. among the participants who agreed to participate in the study, the sociodemographic and menstrual characteristics information form and the visual analogue scale value of 5 and above on the day when the menstrual cycle is most severe were included in the study, and the mcgill pain questionnaire-short form, menstruation attitude scale (mbi), functional and emotional dysmenorrhea scale (feds) they will be asked to fill in. after the groups are formed, video home exercise programs will be delivered online (whatsapp, mail, etc.) to the participants. individuals will be asked to apply the created video home exercise program individually in their own environment. before the participants start their exercise programs, exercise programs will be taught by online interview. you will be asked to do the exercises for 8 weeks, 3 days a week. after the 8-week exercise program is over, the participants will be asked to fill in the mcgill pain questionnaire- short form, menstruation attitude scale (mbi), functional and emotional dysmenorrhea scale (feds) on the day when the menstrual pain is most severe. pre- and post-intervention data were statistically analyzed and compared.

Eligibility criteria:
inclusion criteria: * having a normal menstrual cycle (24-35 days), * never having given birth * according to the visual analogue scale (vas), the pain level during the menstruation period is 10. * to give a score of 5 or more out of cooperative and oriented * volunteer to participate in the study. exclusion criteria: * having an active sexual life * receiving psychiatric treatment for stress disorder or anxiety, using birth control pills, * those with irregular menstrual cycles (less than 21 days or longer than 35 days) * those with a menstrual cycle period), * undergoing any gynecological surgery, * a mental, cardiovascular, pulmonary, or orthopedic disorder that may interfere with exercise have a disease

Keywords: dysmenorrhea menstrual symptom imagination relaxation pelvic floor exercises exercise
response to hepatitis b vaccine in celiac disease patients

Conditions: Celiac Disease

Summary: celiac disease and infection with hepatitis b virus (hbv) are very prevalent worldwide and carry a high morbidity rate. it has been recently shown that patients with celiac disease very often fail to develop immunity after standard vaccination for hbv during infancy. in this study, we will evaluate whether a second vaccination series via a different route of administration (into the skin rather than the muscle) results in a better immunological response in celiac patients. eligible patients will be randomized to receive a 3-dose vaccination series into the skin or to the muscle. rate of responders and level of immunity will be compared. this study will facilitate better protection of celiac patients to this potentially deadly virus.


Eligibility criteria:
inclusion criteria: * patients above 1 year of age with confirmed diagnosis of celiac disease by characteristic symptoms, serology and small bowel biopsy. * completion of the im hbv vaccine series in infancy. * hbsab titer of ≤10miu/ml at the time of enrollment. exclusion criteria: * immunocompromised subjects or those receiving medications that may modulate or suppress the immune system (i.e. azathiopurine, 6-mp, steroids). * inability to obtain written informed consent and patients' assent, as appropriate by the maturity age.

Keywords: celiac disease hepatitis b vaccine
antimullerian hormone in endometriomas

Conditions: Endometriomas

Summary: the purpose of this multicenter study is to evaluate the ovarian reserve after alcohol sclerotherapy of endometriomas versus conventional surgery.

between 5-10% fertile women are affected by endometriosis, and ovarian endometrioma is present in 17-44% of cases, with 40% of patients with endometriomas being sterile. however, the "gold standard" treatment is laparoscopic ovarian cystectomy and this therapy is associated with a diminished ovarian reserve, with a significant antimullerian hormone (amh) decrease. alcohol sclerotherapy is a new minimal invasive procedure in endometrioma treatment whose potential beneficial effect in fertility preservation is not still demonstrated. the investigators would like to demonstrate that this procedure improves fertility preservation and reduces morbidity and costs in contrast with conventional surgery. moreover,the investigators would like to demonstrate that this procedure could be performed in different centers with similar results.

Eligibility criteria:
inclusion criteria: * women * age ≥18 and \<40 years * unilocular endometrioma according ultrasounds * endometrioma size: 35-100 mm during \> 3 months from diagnosis * ca125 \<200 iu/ml and he4 \< 70, * amh previous surgery between 1.2-4 ng/ml exclusion criteria: * previous ovarian surgery or gynecological cancer * severe extraovarian endometriosis * dermoid or high risk of malignancy cysts * hormonal treatment 3 months before * pregnancy * mental disability